CAPS

SEC Filing Summary: OrthoLogic Corp. (dba Capstone Therapeutics)

Business Context and Reporting Period

This Form 10-K covers the fiscal year ended December 31, 2009. OrthoLogic Corp., operating as Capstone Therapeutics, is a biotechnology company in the development stage. The company sold its former revenue-generating bone device business in 2003 and now focuses exclusively on developing two peptide-based therapeutic platforms: AZX100 (targeting smooth muscle relaxation and fibrosis) and Chrysalin (targeting tissue repair and angiogenesis). The company has incurred cumulative net losses of approximately $126 million since becoming a development-stage entity in 2004.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. The company reported an income tax benefit of $1.0 million in 2009 due to a federal tax carryback provision.

Material Changes vs. Prior Period

• Increased Net Loss: The net loss increased by $1.9 million (17%) year-over-year, primarily driven by higher R&D spending on AZX100 Phase 2 clinical trials and reduced interest income due to lower rates and reduced investment balances.
• Decline in Liquidity: Cash and cash equivalents decreased by approximately $10.2 million, reflecting operating cash outflows of $12.8 million. Total assets declined by $12.4 million.
• R&D Focus: R&D expenses rose by $1.3 million, with the substantial majority allocated to AZX100 development. The company completed enrollment for Phase 2 trials in keloid scar revision and dermal scarring in 2009.
• Strategic Shift for Chrysalin: The company confirmed it is not planning additional clinical trials for Chrysalin, instead focusing on pre-clinical vascular studies and seeking licensing or partnering opportunities.

Guidance, Outlook, and Risks

Outlook: Management anticipates that current cash and short-term investments ($35.2 million total) are sufficient to meet projected requirements for the next year. However, the company explicitly states that additional capital will be required to complete clinical trials and obtain FDA approval for its product candidates. Future funding may come from equity sales, joint ventures, or licensing agreements.

Risks and Contingencies:

• Regulatory Risk: No products are currently approved. Success depends on FDA approval, which is uncertain and costly.
• Liquidity Risk: As a development-stage company with no revenue, the company relies entirely on cash reserves and potential future financing.
• Legal Proceedings: The company is named in a qui tam complaint regarding its former bone device business (sold in 2003). The complaint alleges violations of the False Claims Act. The company intends to dismiss the case and believes it will not have a material financial impact.
• Stock Listing: The company transferred its listing from the Nasdaq Global Market to the Nasdaq Capital Market in late 2009 due to minimum bid price violations but is currently in compliance.

Investor Verification Checklist

• Cash Runway: Verify if the $35.2 million in liquid assets is sufficient to fund the completion of AZX100 Phase 2 trials and subsequent regulatory filings without immediate dilution.
• AZX100 Trial Data: Monitor the release of Phase 2 clinical trial results for keloid scar revision and dermal scarring, expected in 2010.
• Chrysalin Partnerships: Assess progress in securing licensing or partnership deals for Chrysalin, as the company has ceased independent clinical development for this platform.
• Legal Status: Track the status of the pending motion to dismiss the qui tam lawsuit related to the divested bone device business.
• Dilution Potential: Review outstanding options (approx. 3.3 million shares) and warrants (approx. 404,000 shares) and the potential for future equity raises.